Intrinsic capacity (IC) represents a paradigm shift in geriatric internal medicine, focusing on the composite of an older adult's physical and mental capacities rather than solely on disease states. This review provides an in-depth, evidence-based discussion on the assessment of intrinsic capacity, its epidemiological significance, clinical features, and the latest advances in management, with an emphasis on practical application for healthcare professionals. Emerging research and guideline recommendations are also explored, highlighting the clinical relevance of IC in optimizing healthy aging and care outcomes.
The concept of intrinsic capacity is gaining prominence as a core framework in geriatric medicine, underpinning proactive approaches to healthy aging. Defined by the World Health Organization (WHO), intrinsic capacity encompasses the composite of all the physical and mental capacities that an individual can draw on. Assessment of IC shifts the clinical focus from the management of individual diseases to the maintenance and enhancement of overall functional ability. This approach aligns with the increasing demand for patient-centered care and has profound implications for clinical practice, research, and policy in geriatric internal medicine.
The global aging population is expanding rapidly. According to the United Nations, by 2050, 1 in 6 people worldwide will be over 65 years old. The burden of functional decline, frailty, and disability is expected to escalate in parallel, contributing significantly to morbidity, mortality, healthcare utilization, and societal costs. Studies indicate that diminished IC is a strong predictor of adverse outcomes, including falls, hospitalization, loss of independence, and mortality. Epidemiological analyses reveal that declines in IC domains often precede overt disability, underscoring the need for early assessment and intervention in geriatric populations.
Intrinsic capacity is determined by the interplay of multiple physiological systems, including locomotor, cognitive, psychological, sensory, and vitality domains. Age-related changes such as sarcopenia, neurodegeneration, hormonal alterations, and immunosenescence progressively impair these domains. Chronic inflammation, oxidative stress, and vascular dysfunction further contribute to the decline in physical and mental reserves. The pathophysiological processes underlying IC decline are multifactorial and cumulative, often exacerbated by comorbidities and environmental factors. Understanding these mechanisms is essential for developing targeted interventions to preserve or restore IC in older adults.
Numerous risk factors accelerate the decline of intrinsic capacity. These include advanced age, polypharmacy, chronic diseases (e.g., diabetes, cardiovascular disease), malnutrition, sedentary lifestyle, social isolation, and multimorbidity. Environmental determinants, such as inadequate access to healthcare, poor social support, and socioeconomic disadvantage, also play pivotal roles. Genetic predisposition and early-life exposures may set the trajectory for later-life IC. Identification and modification of these risk factors are central to prevention strategies in geriatric internal medicine.
Clinical manifestations of declining intrinsic capacity vary across its domains. In the locomotor domain, reduced gait speed, muscle weakness, and impaired balance are common. Cognitive decline presents as memory impairment, reduced executive function, or delirium. Psychological domain impairment manifests as depression, anxiety, or apathy. Sensory deficits include hearing and vision loss, while vitality encompasses fatigue, weight loss, and reduced energy. Early recognition of subtle changes in these domains can facilitate timely intervention, preventing progression to disability and dependency.
Assessment of intrinsic capacity is best achieved through multidimensional tools that evaluate the five core domains: locomotor, cognitive, psychological, sensory, and vitality. The WHO Integrated Care for Older People (ICOPE) screening tool is widely endorsed for use in clinical and community settings. Other validated instruments include the Short Physical Performance Battery (SPPB), Mini-Mental State Examination (MMSE), Geriatric Depression Scale (GDS), and sensory screening protocols. Comprehensive geriatric assessment (CGA) remains the gold standard for holistic evaluation. Biomarkers and digital health technologies are emerging as adjuncts for IC monitoring. Regular, proactive assessment is recommended to tailor individualized care plans.
Management of intrinsic capacity decline involves multi-domain interventions aimed at optimizing physical and mental reserves. Exercise programs, particularly multicomponent regimens incorporating resistance, balance, and aerobic training, are strongly supported by evidence. Cognitive stimulation, nutritional optimization (including protein and vitamin D supplementation), medication review, sensory rehabilitation (hearing aids, cataract surgery), and psychosocial support are vital components. Multidisciplinary teams, including geriatricians, physical therapists, dietitians, and mental health professionals, are essential to deliver comprehensive, patient-centered interventions. Early intervention is key to maintaining functional independence.
Recent research has yielded innovative approaches to intrinsic capacity assessment and enhancement. Digital health technologies, such as wearable devices and mobile applications, allow continuous monitoring of physical activity, cognitive performance, and physiological parameters. Telehealth platforms facilitate remote IC assessment and intervention delivery. Pharmacological research is exploring agents targeting sarcopenia, neuroprotection, and mood disorders. Personalized medicine, leveraging genomics and biomarkers, holds promise for tailored interventions. Emerging data underscore the effectiveness of integrated care models, such as the ICOPE framework, in improving IC and related outcomes at the population level.
International guidelines, notably from the WHO, advocate routine assessment of intrinsic capacity as part of comprehensive geriatric care. The ICOPE framework recommends regular screening of all five IC domains and individualized care planning based on assessment results. Guidelines emphasize the importance of multidisciplinary, person-centered interventions and the integration of IC assessment into primary care and population health strategies. The European Geriatric Medicine Society and other professional bodies endorse similar approaches, highlighting the role of IC in early identification of at-risk older adults and prevention of disability.
Intrinsic capacity assessment represents a transformative approach in geriatric internal medicine, shifting the focus from disease-centric models to the holistic preservation of physical and mental capacities. Early and systematic evaluation of IC domains, combined with evidence-based, individualized interventions, can significantly enhance healthspan, independence, and quality of life in older adults. Ongoing research and guideline-driven practice will continue to refine IC assessment and management, positioning it as a cornerstone for healthy aging in clinical and public health contexts.
1.
Adding Isatuximab to Standard Backbone Prolongs PFS in Myeloma
2.
According to new studies, some cancer patients can safely forego radiation therapy.
3.
According to a study, male testicular cancer risk is linked to neurodevelopmental disorders.
4.
Adding Lenvatinib to Pembro Ups PFS in Head and Neck Cancer
5.
Accelerating the Evidence-Based Integration of Menin Inhibitors Into R/R AML Care: A Live Expert TheraTalk
1.
Unlocking the Secrets of Hemoglobin: How It Works to Keep Us Healthy
2.
Studying Lactic Acid in Pediatric Tumor Microenvironments: Experimental Approaches Explored
3.
Community-Based Cancer Survivorship Support Systems
4.
Omitting Axillary Dissection in Node-Positive Breast Cancer: Insights from the SENOMAC Trial
5.
Early Diagnosis of Lung Cancer Through Emerging Biomarkers
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
1.
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
3.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
4.
Navigating the Complexities of Ph Negative ALL - Part III
5.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation